KMT2A and acute leukemia: The antitumor activity of DS-1594a·HCl and DS-1594a·succinate was reflected in the significant survival benefit in the aggressive disseminated leukemia model intravenously inoculated with MOLM-13 cells and in PDX models of MLL1-r or NPM1c acute leukemia.